PDF(Pubmed)
Abstract：
BACKGROUND: Elevation of systemic inflammatory markers were found to correlate with increased disease extent, reduced lung function and higher risk of future severe exacerbations in patients with bronchiectasis. Although a significant correlation of circulating hs-CRP levels with HRCT scores and resting oxygen saturation in patients with stable-state non-cystic fibrosis (CF) bronchiectasis was suggested, there is little data on the relationship between hs-CRP and the prognosis of bronchiectasis and a lack of data on the role of hs-CRP in predicting bronchiectasis exacerbation.
METHODS: A prospective study was conducted on Chinese patients with non- CF bronchiectasis from 1st October to 31st December 2021. Baseline serum hs-CRP were obtained at stable-state. The follow-up period lasted for one year. Co-primary endpoints were the development of any bronchiectasis exacerbation and hospitalized bronchiectasis exacerbation.
RESULTS: Totally 123 patients were included. Higher hs-CRP was associated with increased risk to develop any bronchiectasis exacerbation, adjusted odds ratio (aOR) of 2.254 (95% CI = 1.040-4.885, p = 0.039), and borderline significantly increased hospitalized bronchiectasis exacerbation with aOR of 1.985 (95% CI = 0.922-4.277, p = 0.080).
CONCLUSIONS: Baseline serum hs-CRP level at stable-state can predict risk of bronchiectasis exacerbation, which is reflecting chronic low-grade inflammation in bronchiectasis.
METHODS: A prospective study was conducted on Chinese patients with non- CF bronchiectasis from 1st October to 31st December 2021. Baseline serum hs-CRP were obtained at stable-state. The follow-up period lasted for one year. Co-primary endpoints were the development of any bronchiectasis exacerbation and hospitalized bronchiectasis exacerbation.
RESULTS: Totally 123 patients were included. Higher hs-CRP was associated with increased risk to develop any bronchiectasis exacerbation, adjusted odds ratio (aOR) of 2.254 (95% CI = 1.040-4.885, p = 0.039), and borderline significantly increased hospitalized bronchiectasis exacerbation with aOR of 1.985 (95% CI = 0.922-4.277, p = 0.080).
CONCLUSIONS: Baseline serum hs-CRP level at stable-state can predict risk of bronchiectasis exacerbation, which is reflecting chronic low-grade inflammation in bronchiectasis.
摘要：
背景：发现全身性炎症标志物的升高与疾病程度增加有关，支气管扩张患者的肺功能降低和未来严重加重的风险增加。尽管在患有稳定状态非囊性纤维化（CF）支气管扩张症的患者中，循环hs-CRP水平与HRCT评分和静息血氧饱和度显著相关，关于hs-CRP与支气管扩张的预后之间的关系的数据很少,而且缺乏关于hs-CRP在预测支气管扩张加重中的作用的数据.
方法：一项前瞻性研究于2021年10月1日至12月31日对中国非CF支气管扩张患者进行。在稳定的状态下获得基线血清hs-CRP。随访期为一年。共同主要终点是任何支气管扩张恶化和住院支气管扩张恶化的发展。
结果：共纳入123例患者。较高的hs-CRP与发生支气管扩张恶化的风险增加有关，调整后的比值比(AOR)为2.254(95%CI=1.040-4.885，p=0.039)，和临界显著增加住院支气管扩张加重,aOR为1.985(95%CI=0.922-4.277,p=0.080)。
结论：稳定状态下的基线血清hs-CRP水平可以预测支气管扩张加重的风险，这反映了支气管扩张的慢性低度炎症。
方法：一项前瞻性研究于2021年10月1日至12月31日对中国非CF支气管扩张患者进行。在稳定的状态下获得基线血清hs-CRP。随访期为一年。共同主要终点是任何支气管扩张恶化和住院支气管扩张恶化的发展。
结果：共纳入123例患者。较高的hs-CRP与发生支气管扩张恶化的风险增加有关，调整后的比值比(AOR)为2.254(95%CI=1.040-4.885，p=0.039)，和临界显著增加住院支气管扩张加重,aOR为1.985(95%CI=0.922-4.277,p=0.080)。
结论：稳定状态下的基线血清hs-CRP水平可以预测支气管扩张加重的风险，这反映了支气管扩张的慢性低度炎症。
